Drug
Nucresiran
Nucresiran: highest development phase Phase 3, developed by Alnylam Pharmaceuticals. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Nucresiran NCT07052903 | Phase 3 | Transthyretin Amyloidosis With Cardiomyopathy |
| Nucresiran NCT07223203 | Phase 3 | Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy |
Latest
No recent events.
Follow Nucresiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.